MDT·Medtronic plc

Truist Securities and JPMorgan Chase & Co. have recently adjusted their price targets for Medtronic, reflecting a more cautious view on the company's near-term performance. Truist Securities lowered its price target to $103, while JPMorgan Chase & Co. set a target of $100, both maintaining Hold and Neutral ratings, respectively. These adjustments suggest analysts anticipate moderate growth or stability in MDT's stock, which could influence investor sentiment in the coming weeks. Investors should watch for future analyst revisions and the company's actual performance against these expectations.